Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Brivanib vs Sorafenib in Advanced Hepatocellular Carcinoma
2008-003533-24Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brivanib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Mar 2009; status: completed.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-003533-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003533-24.